128 related articles for article (PubMed ID: 9873172)
21. Relationship between lipid peroxidation and disease activity in patients with Behçet's disease.
Orem A; Efe H; Değer O; Cimşit G; Uydu HA; Vanizor B
J Dermatol Sci; 1997 Nov; 16(1):11-6. PubMed ID: 9438902
[TBL] [Abstract][Full Text] [Related]
22. The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades-Behçet's disease.
Wang LM; Kitteringham N; Mineshita S; Wang JZ; Nomura Y; Koike Y; Miyashita E
Arch Dermatol Res; 1997 Jul; 289(8):444-7. PubMed ID: 9266021
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress and antioxidant defenses in plasma of patients with Behçet's disease.
Köse K; Doğan P; Aşçioğlu M; Erkiliç K; Aşçioğlu O
Tohoku J Exp Med; 1995 Aug; 176(4):239-48. PubMed ID: 8578583
[TBL] [Abstract][Full Text] [Related]
24. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation?
Pay S; Abbasov T; Erdem H; Musabak U; Simsek I; Pekel A; Akdogan A; Sengul A; Dinc A
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S70-5. PubMed ID: 17949555
[TBL] [Abstract][Full Text] [Related]
25. Sister chromatid exchange and micronucleus studies in patients with Behçet's disease.
Karaman A; Kadi M; Kara F
J Cutan Pathol; 2009 Aug; 36(8):831-7. PubMed ID: 19159395
[TBL] [Abstract][Full Text] [Related]
26. [The HLA pattern in Adamantiades-Behçet's disease in Germany. Association of occurrence, clinical symptoms and follow-up in 39 patients].
Zouboulis CC; Büttner P; Djawari D; Kirch W; Keitel W; Garbe C; von Keyserlingk-Eberius HJ; Orfanos CE
Hautarzt; 1993 Feb; 44(2):81-5. PubMed ID: 8449698
[TBL] [Abstract][Full Text] [Related]
27. Oxidant/antioxidant status in men with Behçet's disease.
Taysi S; Demircan B; Akdeniz N; Atasoy M; Sari RA
Clin Rheumatol; 2007 Mar; 26(3):418-22. PubMed ID: 17206395
[TBL] [Abstract][Full Text] [Related]
28. Chromosome and sister chromatid exchange studies in Behcet's patients.
Oztas S; Gullulu G; Tatar A; Astam N; Akyol I; Karakuzu A; Aktas A; Odabas AR
J Dermatol; 2006 Jun; 33(6):406-10. PubMed ID: 16700831
[TBL] [Abstract][Full Text] [Related]
29. Serum paraoxonase activity is decreased in the active stage of Behçet's disease.
Karakucuk S; Baskol G; Oner AO; Baskol M; Mirza E; Ustdal M
Br J Ophthalmol; 2004 Oct; 88(10):1256-8. PubMed ID: 15377545
[TBL] [Abstract][Full Text] [Related]
30. Changes in serum carbonyl and malondialdehyde levels following colchicine and vitamin E treatment in Behcet's disease.
Gulbahar O; Adisen H; Koca C; Aricioglu A; Gulekon A
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):521-4. PubMed ID: 18040527
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress: correlation with Behçet's disease duration, activity and severity.
Harzallah O; Kerkeni A; Baati T; Mahjoub S
Eur J Intern Med; 2008 Nov; 19(7):541-7. PubMed ID: 19013385
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of allantoin levels as a new marker of oxidative stress in Behçet's disease.
Yardim-Akaydin S; Sepici A; Ozkan Y; Simşek B; Sepici V
Scand J Rheumatol; 2006; 35(1):61-4. PubMed ID: 16467045
[TBL] [Abstract][Full Text] [Related]
33. Clastogenic factors in the plasma of patients with hepatitis C: their possible role at the origin of hepatocarcinoma.
Emerit I; Serejo F; Carneiro de Moura M
Cancer Genet Cytogenet; 2007 Nov; 179(1):31-5. PubMed ID: 17981212
[TBL] [Abstract][Full Text] [Related]
34. Adamantiades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate.
Katsantonis J; Adler Y; Orfanos CE; Zouboulis CC
Dermatology; 2000; 201(1):37-9. PubMed ID: 10971057
[TBL] [Abstract][Full Text] [Related]
35. Clastogenic factors as potential biomarkers of increased superoxide production.
Emerit I
Biomark Insights; 2007 Dec; 2():429-38. PubMed ID: 19662223
[TBL] [Abstract][Full Text] [Related]
36. Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C.
Emerit I; Serejo F; Filipe P; Alaoui Youssefi A; Fernandes A; Costa A; Freitas J; Ramalho F; Baptista A; Carneiro de Moura M
Digestion; 2000; 62(2-3):200-7. PubMed ID: 11025369
[TBL] [Abstract][Full Text] [Related]
37. Serum YKL-40 and MDA levels in Behcet disease.
Bilen H; Altinkaynak K; Sebin E; Aksoy H; Akcay F
J Pak Med Assoc; 2016 Oct; 66(10):1299-1302. PubMed ID: 27686308
[TBL] [Abstract][Full Text] [Related]
38. Erythrocyte antioxidant activity and trace element levels in Behçet's disease.
Tüzün A; Aydin A; Turan M
Biol Trace Elem Res; 1998; 64(1-3):169-74. PubMed ID: 9845471
[TBL] [Abstract][Full Text] [Related]
39. Monocyte-derived clastogenic factor in rheumatoid arthritis.
Emerit I; Levy A; Camus JP
Free Radic Biol Med; 1989; 6(3):245-50. PubMed ID: 2744575
[TBL] [Abstract][Full Text] [Related]
40. Multiparameter analysis of clastogenic factors, pro-oxidant cytokines, and inflammatory markers in HIV-1-infected patients with asymptomatic disease, opportunistic infections, and malignancies.
Fuchs J; Oelke N; Imhof M; Ochsendorf F; Schöfer H; Oromek G; Alaoui-Youssefi A; Emerit I
Mol Med; 1998 May; 4(5):333-43. PubMed ID: 9642683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
